Ultragenyx Pharmaceutical (RARE) Net Cash Flow Growth (5y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.66% |
| Dec 31, 2025 | -15.81% |
| Sep 30, 2025 | 16.93% |
| Jun 30, 2025 | 4.42% |
| Mar 31, 2025 | 19.39% |
| Dec 31, 2024 | -39.05% |
| Sep 30, 2024 | -109.10% |
| Jun 30, 2024 | 36.09% |
| Mar 31, 2024 | -21.20% |
| Dec 31, 2023 | 36.00% |
| Sep 30, 2023 | -0.30% |
| Jun 30, 2023 | 16.45% |
| Mar 31, 2023 | -18.81% |
| Dec 31, 2022 | -53.42% |
| Sep 30, 2022 | 57.21% |
| Jun 30, 2022 | 16.14% |
| Mar 31, 2022 | -121.79% |
| Dec 31, 2021 | 37.95% |
| Sep 30, 2021 | -25.11% |
| Jun 30, 2021 | -43.04% |
| Mar 31, 2021 | -70.55% |
| Dec 31, 2020 | 55.81% |
| Sep 30, 2020 | -26.29% |
| Jun 30, 2020 | 18.07% |
| Mar 31, 2020 | -23.53% |
| Dec 31, 2019 | 66.22% |
| Sep 30, 2019 | -17.40% |
| Jun 30, 2019 | -29.46% |
| Mar 31, 2019 | 26.68% |
| Dec 31, 2018 | 85.11% |
| Sep 30, 2018 | -30.22% |
| Jun 30, 2018 | -17.52% |
| Mar 31, 2018 | 51.14% |